ABL Diagnostics SA (ABLD) Price & Analysis

ABL Diagnostics Société anonyme, headquartered in Woippy, France, offers exclusive molecular biology assays and complete, end-to-end solutions for molecular detection, utilizing both polymerase chain reaction (PCR) and DNA sequencing technologies for clients in France and worldwide. Its comprehensive offerings encompass genetic profiling, or genotyping, performed through NGS and Sanger sequencing for critical pathogens like human immunodeficiency virus (HIV), SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA. Additionally, Ultragene assays are provided for detecting viruses such as SARS CoV-2, MonkeyPox, and Clostridium. The firm also furnishes microbiological specimen collection and transport kits, which feature materials for saliva preservation, wastewater and surface collection, alongside inactivation and preservation solutions. Critical laboratory equipment and consumables are also part of their inventory, including DNA/RNA extraction systems, real-time PCR devices, liquid handling robotics, NGS library preparation kits, and reagents for Sanger sequencing. Complementing these, a range of digital tools is available, comprising analysis software, data hosting services, lab automation platforms, Nadis, and SeqHepB. ABL Diagnostics reaches its clientele – academic clinical pathology laboratories, private reference facilities, and research institutions – via both direct sales and an extensive distributor network. The entity, previously named Etablissements Fauvet Girel, rebranded as ABL Diagnostics Société anonyme in April 2022 and functions as a subsidiary of Advanced Biological Laboratories (ABL) S.A.